Jie Lin1, Corey A Carter, Katherine A McGlynn, Shelia H Zahm, Joel A Nations, William F Anderson, Craig D Shriver, Kangmin Zhu. 1. *John P. Murtha Cancer Center, and †Department of Medicine, Walter Reed National Military Medical Center, Bethesda, Maryland; ‡Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland; and Departments of §Surgery and ‖Preventative Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland.
Abstract
INTRODUCTION: Accurate prognosis assessment after non-small-cell lung cancer (NSCLC) diagnosis is an essential step for making effective clinical decisions. This study is aimed to develop a prediction model with routinely available variables to assess prognosis in patients with NSCLC in the U.S. Military Health System. METHODS: We used the linked database from the Department of Defense's Central Cancer Registry and the Military Health System Data Repository. The data set was randomly and equally split into a training set to guide model development and a testing set to validate the model prediction. Stepwise Cox regression was used to identify predictors of survival. Model performance was assessed by calculating area under the receiver operating curves and construction of calibration plots. A simple risk scoring system was developed to aid quick risk score calculation and risk estimation for NSCLC clinical management. RESULTS: The study subjects were 5054 patients diagnosed with NSCLC between 1998 and 2007. Age, sex, tobacco use, tumor stage, histology, surgery, chemotherapy, peripheral vascular disease, cerebrovascular disease, and diabetes mellitus were identified as significant predictors of survival. Calibration showed high agreement between predicted and observed event rates. The area under the receiver operating curves reached 0.841, 0.849, 0.848, and 0.838 during 1, 2, 3, and 5 years, respectively. CONCLUSIONS: This is the first NSCLC prognosis model for quick risk assessment within the Military Health System. After external validation, the model can be translated into clinical use both as a web-based tool and through mobile applications easily accessible to physicians, patients, and researchers.
INTRODUCTION: Accurate prognosis assessment after non-small-cell lung cancer (NSCLC) diagnosis is an essential step for making effective clinical decisions. This study is aimed to develop a prediction model with routinely available variables to assess prognosis in patients with NSCLC in the U.S. Military Health System. METHODS: We used the linked database from the Department of Defense's Central Cancer Registry and the Military Health System Data Repository. The data set was randomly and equally split into a training set to guide model development and a testing set to validate the model prediction. Stepwise Cox regression was used to identify predictors of survival. Model performance was assessed by calculating area under the receiver operating curves and construction of calibration plots. A simple risk scoring system was developed to aid quick risk score calculation and risk estimation for NSCLC clinical management. RESULTS: The study subjects were 5054 patients diagnosed with NSCLC between 1998 and 2007. Age, sex, tobacco use, tumor stage, histology, surgery, chemotherapy, peripheral vascular disease, cerebrovascular disease, and diabetes mellitus were identified as significant predictors of survival. Calibration showed high agreement between predicted and observed event rates. The area under the receiver operating curves reached 0.841, 0.849, 0.848, and 0.838 during 1, 2, 3, and 5 years, respectively. CONCLUSIONS: This is the first NSCLC prognosis model for quick risk assessment within the Military Health System. After external validation, the model can be translated into clinical use both as a web-based tool and through mobile applications easily accessible to physicians, patients, and researchers.
Authors: Richard J Battafarano; Jay F Piccirillo; Bryan F Meyers; Han-Shui Hsu; Tracey J Guthrie; Joel D Cooper; G Alexander Patterson Journal: J Thorac Cardiovasc Surg Date: 2002-02 Impact factor: 5.209
Authors: Lindsey Enewold; Jing Zhou; Katherine A McGlynn; William F Anderson; Craig D Shriver; John F Potter; Shelia H Zahm; Kangmin Zhu Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: Daniel H Ahn; Nishi Mehta; Jeffrey T Yorio; Yang Xie; Jingsheng Yan; David E Gerber Journal: Clin Lung Cancer Date: 2013-07-22 Impact factor: 4.785
Authors: Brent A Williams; Hiroshi Sugimura; Chiaki Endo; Francis C Nichols; Stephen D Cassivi; Mark S Allen; Peter C Pairolero; Claude Deschamps; Ping Yang Journal: Ann Thorac Surg Date: 2006-03 Impact factor: 4.330
Authors: Jie Lin; Abegail Gill; Shelia H Zahm; Corey A Carter; Craig D Shriver; Joel A Nations; William F Anderson; Katherine A McGlynn; Kangmin Zhu Journal: Int J Cancer Date: 2017-05-04 Impact factor: 7.396
Authors: Oscar Arrieta; Edgar Varela-Santoyo; Enrique Soto-Perez-de-Celis; Roberto Sánchez-Reyes; Martha De la Torre-Vallejo; Saé Muñiz-Hernández; Andrés F Cardona Journal: BMC Cancer Date: 2016-08-12 Impact factor: 4.430
Authors: D Révész; E G Engelhardt; J J Tamminga; F M N H Schramel; B D Onwuteaka-Philipsen; E M W van de Garde; E W Steyerberg; E P Jansma; H C W De Vet; V M H Coupé Journal: BMC Med Inform Decis Mak Date: 2017-10-02 Impact factor: 2.796
Authors: Arthur Jochems; Turkey Refaee; Henry C Woodruff; Philippe Lambin; Guangyao Wu; Abdalla Ibrahim; Chenggong Yan; Sebastian Sanduleanu Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-11 Impact factor: 10.057